Optimize radiochemotherapy in pancreatic cancer

PARP inhibitors a new therapeutic opportunity

Letizia Porcelli, Anna E. Quatrale, Paola Mantuano, Maria G. Leo, Nicola Silvestris, Jean F. Rolland, Enza Carioggia, Marco Lioce, Angelo Paradiso, Amalia Azzariti

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Cancer cells may use PARP enzymes and Homologous Recombination to repair single and double strand breaks caused by genotoxic insults. In this study, the PARP-1 inhibitor Rucaparib was utilized to increase the sensitivity to chemoradiotherapy treatment in BRCA-2-deficient and -proficient pancreatic cancer cells. We used the pancreatic cancer cell lines, Capan-1 with mutated BRCA-2 and Panc-1, AsPC-1 and MiaPaCa-2 with BRCA-1/2 wild type. Cells were treated with Rucaparib and/or radiotherapy (4-10 Gy) plus Gemcitabine then the capability to proliferate was evaluated by colony formation, cell counting and MTT assays. Flow cytometry, immunocytochemistry and western blotting were utilized to assess cell response to Rucaparib plus irradiation. The antitumour effectiveness of combining the PARP-1 inhibitor before, together and after radiotherapy evidenced the first as the optimal schedule in blocking cell growth. Pre-exposure to Rucaparib increased the cytotoxicity of Gemcitabine plus radiotherapy by heavily inducing the accumulation of cells in G2/M phase, impairing mitosis and finally inducing apoptosis and authophagy. The upregulation of p-Akt and downregulation of p53 were evidenced in MiaPaCa-2 which displayed replication stress features. For the first time, the rationale of using a PARP inhibitor as chemoradiosensitizer in pancreatic cancer models has been hypothesized and demonstrated.

Original languageEnglish
Pages (from-to)308-322
Number of pages15
JournalMolecular Oncology
Volume7
Issue number3
DOIs
Publication statusPublished - Jun 2013

Fingerprint

Chemoradiotherapy
Pancreatic Neoplasms
gemcitabine
Radiotherapy
Therapeutics
Recombinational DNA Repair
G2 Phase
Poly(ADP-ribose) Polymerase Inhibitors
Mitosis
Cell Division
Appointments and Schedules
Flow Cytometry
Up-Regulation
Down-Regulation
Western Blotting
Immunohistochemistry
Apoptosis
Cell Line
rucaparib
Enzymes

Keywords

  • Chemoradiotherapy
  • Gemcitabine
  • Pancreatic cancer
  • PARP inhibitor
  • Rucaparib

ASJC Scopus subject areas

  • Cancer Research
  • Genetics
  • Molecular Medicine

Cite this

Porcelli, L., Quatrale, A. E., Mantuano, P., Leo, M. G., Silvestris, N., Rolland, J. F., ... Azzariti, A. (2013). Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity. Molecular Oncology, 7(3), 308-322. https://doi.org/10.1016/j.molonc.2012.10.002

Optimize radiochemotherapy in pancreatic cancer : PARP inhibitors a new therapeutic opportunity. / Porcelli, Letizia; Quatrale, Anna E.; Mantuano, Paola; Leo, Maria G.; Silvestris, Nicola; Rolland, Jean F.; Carioggia, Enza; Lioce, Marco; Paradiso, Angelo; Azzariti, Amalia.

In: Molecular Oncology, Vol. 7, No. 3, 06.2013, p. 308-322.

Research output: Contribution to journalArticle

Porcelli, Letizia ; Quatrale, Anna E. ; Mantuano, Paola ; Leo, Maria G. ; Silvestris, Nicola ; Rolland, Jean F. ; Carioggia, Enza ; Lioce, Marco ; Paradiso, Angelo ; Azzariti, Amalia. / Optimize radiochemotherapy in pancreatic cancer : PARP inhibitors a new therapeutic opportunity. In: Molecular Oncology. 2013 ; Vol. 7, No. 3. pp. 308-322.
@article{51c707ba028f47d4ba013a55d90f7dc9,
title = "Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity",
abstract = "Cancer cells may use PARP enzymes and Homologous Recombination to repair single and double strand breaks caused by genotoxic insults. In this study, the PARP-1 inhibitor Rucaparib was utilized to increase the sensitivity to chemoradiotherapy treatment in BRCA-2-deficient and -proficient pancreatic cancer cells. We used the pancreatic cancer cell lines, Capan-1 with mutated BRCA-2 and Panc-1, AsPC-1 and MiaPaCa-2 with BRCA-1/2 wild type. Cells were treated with Rucaparib and/or radiotherapy (4-10 Gy) plus Gemcitabine then the capability to proliferate was evaluated by colony formation, cell counting and MTT assays. Flow cytometry, immunocytochemistry and western blotting were utilized to assess cell response to Rucaparib plus irradiation. The antitumour effectiveness of combining the PARP-1 inhibitor before, together and after radiotherapy evidenced the first as the optimal schedule in blocking cell growth. Pre-exposure to Rucaparib increased the cytotoxicity of Gemcitabine plus radiotherapy by heavily inducing the accumulation of cells in G2/M phase, impairing mitosis and finally inducing apoptosis and authophagy. The upregulation of p-Akt and downregulation of p53 were evidenced in MiaPaCa-2 which displayed replication stress features. For the first time, the rationale of using a PARP inhibitor as chemoradiosensitizer in pancreatic cancer models has been hypothesized and demonstrated.",
keywords = "Chemoradiotherapy, Gemcitabine, Pancreatic cancer, PARP inhibitor, Rucaparib",
author = "Letizia Porcelli and Quatrale, {Anna E.} and Paola Mantuano and Leo, {Maria G.} and Nicola Silvestris and Rolland, {Jean F.} and Enza Carioggia and Marco Lioce and Angelo Paradiso and Amalia Azzariti",
year = "2013",
month = "6",
doi = "10.1016/j.molonc.2012.10.002",
language = "English",
volume = "7",
pages = "308--322",
journal = "Molecular Oncology",
issn = "1574-7891",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Optimize radiochemotherapy in pancreatic cancer

T2 - PARP inhibitors a new therapeutic opportunity

AU - Porcelli, Letizia

AU - Quatrale, Anna E.

AU - Mantuano, Paola

AU - Leo, Maria G.

AU - Silvestris, Nicola

AU - Rolland, Jean F.

AU - Carioggia, Enza

AU - Lioce, Marco

AU - Paradiso, Angelo

AU - Azzariti, Amalia

PY - 2013/6

Y1 - 2013/6

N2 - Cancer cells may use PARP enzymes and Homologous Recombination to repair single and double strand breaks caused by genotoxic insults. In this study, the PARP-1 inhibitor Rucaparib was utilized to increase the sensitivity to chemoradiotherapy treatment in BRCA-2-deficient and -proficient pancreatic cancer cells. We used the pancreatic cancer cell lines, Capan-1 with mutated BRCA-2 and Panc-1, AsPC-1 and MiaPaCa-2 with BRCA-1/2 wild type. Cells were treated with Rucaparib and/or radiotherapy (4-10 Gy) plus Gemcitabine then the capability to proliferate was evaluated by colony formation, cell counting and MTT assays. Flow cytometry, immunocytochemistry and western blotting were utilized to assess cell response to Rucaparib plus irradiation. The antitumour effectiveness of combining the PARP-1 inhibitor before, together and after radiotherapy evidenced the first as the optimal schedule in blocking cell growth. Pre-exposure to Rucaparib increased the cytotoxicity of Gemcitabine plus radiotherapy by heavily inducing the accumulation of cells in G2/M phase, impairing mitosis and finally inducing apoptosis and authophagy. The upregulation of p-Akt and downregulation of p53 were evidenced in MiaPaCa-2 which displayed replication stress features. For the first time, the rationale of using a PARP inhibitor as chemoradiosensitizer in pancreatic cancer models has been hypothesized and demonstrated.

AB - Cancer cells may use PARP enzymes and Homologous Recombination to repair single and double strand breaks caused by genotoxic insults. In this study, the PARP-1 inhibitor Rucaparib was utilized to increase the sensitivity to chemoradiotherapy treatment in BRCA-2-deficient and -proficient pancreatic cancer cells. We used the pancreatic cancer cell lines, Capan-1 with mutated BRCA-2 and Panc-1, AsPC-1 and MiaPaCa-2 with BRCA-1/2 wild type. Cells were treated with Rucaparib and/or radiotherapy (4-10 Gy) plus Gemcitabine then the capability to proliferate was evaluated by colony formation, cell counting and MTT assays. Flow cytometry, immunocytochemistry and western blotting were utilized to assess cell response to Rucaparib plus irradiation. The antitumour effectiveness of combining the PARP-1 inhibitor before, together and after radiotherapy evidenced the first as the optimal schedule in blocking cell growth. Pre-exposure to Rucaparib increased the cytotoxicity of Gemcitabine plus radiotherapy by heavily inducing the accumulation of cells in G2/M phase, impairing mitosis and finally inducing apoptosis and authophagy. The upregulation of p-Akt and downregulation of p53 were evidenced in MiaPaCa-2 which displayed replication stress features. For the first time, the rationale of using a PARP inhibitor as chemoradiosensitizer in pancreatic cancer models has been hypothesized and demonstrated.

KW - Chemoradiotherapy

KW - Gemcitabine

KW - Pancreatic cancer

KW - PARP inhibitor

KW - Rucaparib

UR - http://www.scopus.com/inward/record.url?scp=84878112437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878112437&partnerID=8YFLogxK

U2 - 10.1016/j.molonc.2012.10.002

DO - 10.1016/j.molonc.2012.10.002

M3 - Article

VL - 7

SP - 308

EP - 322

JO - Molecular Oncology

JF - Molecular Oncology

SN - 1574-7891

IS - 3

ER -